This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goldstein, E. J. C.
Right arrow Articles by Fernandez, H. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldstein, E. J. C.
Right arrow Articles by Fernandez, H. T.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2008, p. 761-766, Vol. 52, No. 2
0066-4804/08/$08.00+0     doi:10.1128/AAC.01128-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

In Vitro Activities of Doripenem and Six Comparator Drugs against 423 Aerobic and Anaerobic Bacterial Isolates from Infected Diabetic Foot Wounds{triangledown}

Ellie J. C. Goldstein,1,2* Diane M. Citron,1 C. Vreni Merriam,1 Yumi A. Warren,1 Kerin L. Tyrrell,1 and Helen T. Fernandez1

R M Alden Research Laboratory, Santa Monica, California 90404,1 UCLA School of Medicine, Los Angeles, California 900952

Received 26 August 2007/ Returned for modification 6 October 2007/ Accepted 20 November 2007

Against 182 anaerobe and 241 aerobe strains obtained from diabetic foot infections, doripenem was the most active carbapenem against Pseudomonas aeruginosa (MIC90, 2 µg/ml), more active than imipenem against Proteus mirabilis, and ertapenem was more active against Escherichia coli and Klebsiella spp. The MIC50 and MIC90 values were ≤0.125 µg/ml for methicillin-sensitive Staphylococcus aureus and all streptococci and 0.25/1 for Bacteroides fragilis.

* Corresponding author. Mailing address: R M Alden Research Laboratory, 2021 Santa Monica Blvd., 740 East, Santa Monica, CA 90404. Phone: (310) 315-1511. Fax: (310) 315-3662. E-mail: ejcgmd{at}aol.com

{triangledown} Published ahead of print on 10 December 2007.

Antimicrobial Agents and Chemotherapy, February 2008, p. 761-766, Vol. 52, No. 2
0066-4804/08/$08.00+0     doi:10.1128/AAC.01128-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • El Solh, A. A., Alhajhusain, A. (2009). Update on the treatment of Pseudomonas aeruginosa pneumonia. J Antimicrob Chemother 64: 229-238 [Abstract] [Full Text]  
  • Snydman, D. R., Jacobus, N. V., McDermott, L. A. (2008). In Vitro Activities of Doripenem, a New Broad-Spectrum Carbapenem, against Recently Collected Clinical Anaerobic Isolates, with Emphasis on the Bacteroides fragilis Group. Antimicrob. Agents Chemother. 52: 4492-4496 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»